

Katherine M Dominy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9196887/publications.pdf>

Version: 2024-02-01

11
papers

187
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

310
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue. <i>Clinical Transplantation</i> , 2016, 30, 295-305.	1.6	60
2	Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection. <i>Kidney International Reports</i> , 2019, 4, 148-158.	0.8	33
3	Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 192-203.	3.9	32
4	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 346-355.	2.5	18
5	Use of Quantitative Real Time Polymerase Chain Reaction to Assess Gene Transcripts Associated With Antibody-Mediated Rejection of Kidney Transplants. <i>Transplantation</i> , 2015, 99, 1981-1988.	1.0	15
6	Molecular assessment of antibody-mediated rejection in human pancreas allograft biopsies. <i>Clinical Transplantation</i> , 2020, 34, e14065.	1.6	9
7	Assessment of quantitative polymerase chain reaction for <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?. <i>British Journal of Haematology</i> , 2022, 197, 52-62.	2.5	7
8	Diagnostic application of transcripts associated with antibody-mediated rejection in kidney transplant biopsies. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1576-1584.	0.7	6
9	Molecular Monitoring of Chronic Myeloid Leukemia. <i>Methods in Molecular Biology</i> , 2020, 2065, 153-173.	0.9	4
10	Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , 2020, 43, 53-56.	2.4	2
11	Evaluation of Xpert® BCR-ABL Ultra for the confirmation of <i>BCR-ABL1</i> international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e31-e34.	1.3	1